Abstract
Lung cancer is the leading cause of cancer-related death worldwide. Therefore, improving the lung cancer treatment trajectory is crucial. In metastatic non-small cell lung cancer (NSCLC) the development of oncogene directed therapy has improved survival significantly. In approximately 5% of all NSCLCs the ALK translocation is detected. The standard treatment for metastatic ALK-positive (ALK+) NSCLC is ALK-inhibitors. This treatment is effective, well-tolerated, and several ALK-directed drugs are available for clinical use.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
